Joint interview with Helena Prado and Mamy Jean-Jacques Razafimahatratra
- Home
- Articles Posted by

admin03241305
« Making time for dialogue »
Helena Prado (ORCID 0000-0002-0270-2167) is an Associate Professor of Anthropology at the University of Strasbourg (Institute of Ethnology, Faculty of Social Sciences / Interdisciplinary Laboratory for Cultural Studies). Since 2017 she has done research in the anthropology of health, in particular on representations of the body, reproductive and sexual life, and the social management of vector-borne diseases. Mamy Jean-Jacques Razafimahatratra, PhD (ORCID 0000-0002-7238-5179), has extensive research experience in health and the anthropology of health. He currently heads the Research Division of the National Institute of Public and Community Health (INSP) in Antananarivo, Madagascar. They work alongside Denise Hien (ORCID 0000-0002-7073-6924) from Burkina Faso, who holds a research master’s degree in social and cultural anthropology, is a PhD candidate in the sociology of health at Joseph Ki-Zerbo University in Ouagadougou, and is a sociologist with the Groupe de Recherche Action en Santé (GRAS). Together, the three play a key role in running the socio-anthropological studies and in mobilising and engaging communities in the IMPRIMA project.
Valérie Bisson: Can you each tell us about your background?
Helena Prado: I trained in social and cultural anthropology at the École des Hautes Études en Sciences Sociales (EHESS) in Paris. I only came to the anthropology of health after my PhD. I first worked on maternal and reproductive health during health emergencies, then on the social management of vector-borne diseases such as Zika and malaria.
Mamy Razafimahatratra: I’m a medical doctor first. At the end of my medical studies I specialised in public health, and then I went on to train in the humanities and social sciences and in the anthropology of health. Today I head the Research Division at the National Institute of Public and Community Health (INSP) in Antananarivo, Madagascar. That puts me at the heart of the issues I care about, such as taking the realities of local populations into account.
VB: How did your paths come together in the IMPRIMA project?
HP: Through a series of chance events and opportunities, we both ended up in the working group on the social component of the project, which focuses on malaria and primaquine. IMPRIMA was designed to approach the clinical trial with a socio-anthropological component built in. During my postdoc on the Zika virus in Brazil, I worked at Ceped (Université Paris Cité) alongside several anthropologists and health demographers who were running interdisciplinary projects funded by European donors and the Global Fund. It turned out we had colleagues in common, including Dolorès Pourette, a health anthropologist who works in Madagascar and Réunion.
MR: It was Arsène Ratsimbasoa, whom I’ve worked with for a long time, who first invited me to look at the project. We realised later that Helena and I had in fact already crossed paths. At the IMPRIMA launch in Strasbourg in November 2023, with the consortium and the whole CNARP team, we started working together on WP3. Helena is in Strasbourg and I’m in Madagascar, but we quickly found an easy way to exchange ideas on our subject. We met again soon after, in March 2024 in Madagascar, and then in March 2026 in Leiden, in the Netherlands.
VB: How is the part of the project you’re responsible for, the socio-anthropological study, going?
HP: We started setting up the qualitative survey protocol in March 2024, because we were able to work efficiently in the field. Mamy had many contacts with health professionals in the community health centres. He also has a truly remarkable sense of social ties and relationships, which made our work much easier. Thanks to the trust we had built, I was able to observe a great deal and ask him a lot of questions.
MR: WP3 is built around three main activities. The first is the exploratory study, which gathers people’s knowledge and perceptions of malaria before the clinical component starts, so that it can inform that work. It ended in September 2024 and identified what information and communication the population needs. The second is the KAP (knowledge, attitudes and practices) study, carried out at the project’s midpoint. It gives us a baseline for adapting how the clinical component is rolled out, if needed. Finally, the transfer of skills to local institutions and leaders is planned for the end of the project.
VB: A final word on the project as a whole?
HP: I’d say the project works well because of the idea of connecting the different WPs to one another. Exploring the knowledge, attitudes and perceptions of local people has to interact with the clinical component. That means patients as well as health professionals and community health workers. Each side should feed into the other, with help from the communication activities too. All of this leads to the same goal: the final advocacy work to allow primaquine to be implemented. The idea behind the project, as EDCTP3 designed it and as is now widely documented, is that a health intervention with a new drug can’t succeed without the support of the people it’s meant for. Engaging in dialogue, exchanging views, and aligning everyone’s interests around the fight against malaria, all in both directions, is essential.
Interview by Valérie Bisson at Leiden University, 13 March 2026.
Deploying paediatric formulations: a new primaquine project following on from DPP and IMPRIMA, supported by GH EDCTP3
Our funder GH EDCTP3, which works for global health, has welcomed the extension of the primaquine work carried out with financial support from its programme. The ASAQ-PAC project (No. 101248882, Advancing child-friendly artesunate-amodiaquine taste mask coated micro pellets to combat the threat of artemisinin resistant malaria in Africa) builds on the DPP project and complements the IMPRIMA project. It continues the fight against malaria with a focus on children.
ASAQ-PAC is coordinated by our partner, the University of Oxford / Mahidol University (MORU), with support from ClinSearch, which is also involved in DPP and IMPRIMA. The project comes out of new partnerships: with Kamuzu University of Health Sciences in Malawi for scientific leadership and clinical operations, and with Fluid Pharma and the University of Hertfordshire for pharmaceutical manufacturing. ASAQ-PAC started in June 2026. It aims to evaluate a new paediatric formulation of the artemisinin-based combination therapy (ACT) artesunate-amodiaquine in granule form. The granules will be given with or without a single low dose of primaquine. The primaquine will come as paediatric tablets, using the dosage forms developed in the DPP project and given in the related DPP and IMPRIMA clinical studies.
Each project carries forward the same vision and the same actions for global health and the fight against malaria, especially for children.
Madagascar joins EDCTP
It was with great joy that Rianasoambolanoro Rakotosaona, Director of the Centre National d’Application de Recherches Pharmaceutiques (CNARP), together with Arsène Ratsimbasoa, a medical epidemiologist with a PhD in epidemiology and an expert in clinical research on malaria, and Jackie Andriarison, Head of Communications at CNARP, told the consortium members gathered in Leiden on 13 March 2026 the news: the EDCTP Association had announced that Madagascar was its newest member country. This brings the total number of African member countries to 33.
The General Assembly of the EDCTP Association officially approved Madagascar’s membership on 10 March 2026, which strengthens regional collaboration in global health research.
As a new member, Madagascar gains a major opportunity to build its national capacity in clinical research and clinical trials, and to consolidate its strengths in health and research. Madagascar is building strategic partnerships with other members of the Association, as in the IMPRIMA project with Burkina Faso and Burundi, which also recently joined EDCTP. Through these partnerships, it is becoming a key player in developing innovative solutions to fight infectious diseases across Africa.
CNARP https://cnarp.mg/
EDCTP https://research-and-innovation.ec.europa.eu/research-area/health/edctp_en
IMPRIMA LinkedIn
EDCTP3 LinkedIn
Antsa Nomenjanahary Rakotondrandriana
- Home
- Articles Posted by

admin03241305
"Building bridges"
Antsa Nomenjanahary Rakotondrandriana (ORCID 0000-0002-6890-9152) studied medicine at the Faculty of Antananarivo (Madagascar) and went on to specialise in public health. With a particular interest in clinical research and epidemiology, she joined the Clinical Trials Department of the National Centre for Pharmaceutical Research Applications (CNARP) in 2021 as a clinical trial investigator.
Valérie Bisson : Could you describe what led you to pursue scientific studies?
Antsa Nomenjanahary Rakotondrandriana : I have been interested in medical studies since I was a child. I was fascinated by the functioning of the human body, but also by healthcare. I was very attracted to science and already had the idea of improving everything related to medicine.
My grandfather was a doctor and he inspired me greatly. Healthcare has always been one of my primary concerns. When I was asked as a little girl what I wanted to be when I grew up, I would answer: I want to be a doctor!
V B : How would you define care?
A N R : Medicine is, above all else, a technical act. For me, this act must be accompanied by contact; listening, talking and communicating with empathy are an integral part of care. Suturing and treating also require reassurance. Care is both a medical act and an act of humanity.
V B : Is passing on knowledge part of your responsibilities?
A N R : That’s a very good question; when you love something, you want to pass on your passion to others. I taught medicine at the University of Fianarantsoa, and I enjoyed that experience. Now at CNARP, I have trainees who are interested in medicine, and they ask me for advice. Passing on knowledge and skills is essential. Working in public health requires a collective vision and large-scale dissemination. And I continue to treat and prescribe for CNARP staff.
V B : You moved from public health to clinical research. Could you explain how this shift came about?
A N R : After specialising in public health, I was hired by the CNARP as a doctor and researcher. When you are a doctor, you are already interested in research, as there are always innovations. In my case, I wanted to be able to care for several people at once in order to prevent disease and treat the community. I had to learn how public health works and its specific characteristics, as well as those of research, as they are inseparable. For me, it wasn’t exactly a shift, it was a whole package.
V B : How did you become involved in the IMPRIMA project?
A N R : The IMPRIMA project is an ambitious international project led by several organisations, including the CNARP. It is also a meaningful project, as many people in Madagascar are affected by malaria.
As a research physician at the CNARP, I was selected for this project and I am fully committed to it. The administrative side of things is very demanding, but I see this as a challenge. As a physician-researcher at CNARP, I was chosen for this project and I am 100% committed to it. The administrative aspect is very demanding, and I see this as a challenge. Developing the clinical study documents is a collaborative challenge that allows us to renew our knowledge of good clinical practices, and we are learning a lot from the practices of other countries. IMPRIMA is a tremendous opportunity to broaden our impact and move forward.
V B : Could you describe your vision of research in a few words?
A N R : Learning about medicine in depth has been a vocation, as has learning new things. Scientific innovation is a driving force, and clinical research is a real bridge between data, which can seem abstract, and the malaria patient suffering in their bed, who cannot be treated without specific knowledge about that individual. I like this idea of a bridge between a microscopic vision, which is that of research, and a macroscopic vision, which is that of humanity, humanity in the broad sense in the sense that we work for the collective good.
Interview conducted by Valérie Bisson and Jackie Andriarison on 24 September 2025.
Burundi joins EDCTP
The Burundi National Institute of Public Health (INSP) began operations in 1999. Led since 2018 by Professor Joseph Nyandwi, the INSP’s mission is to strengthen the capacities of the ministry responsible for public health. A multi-purpose centre, it integrates training and research in public health as well as laboratory analysis and environmental monitoring. In this capacity, the INSP strives to provide the Burundian population, particularly the most vulnerable groups, with access to quality preventive, curative and promotional care based on choices informed by scientific evidence.
Involved in the IMPRIMA project (EDCTP 3 funding) since April 2023, the INSP, represented by Joseph Nyandwi and Denis Niyomwungere, has submitted an application enabling the Institute to join the European & Developing Countries Clinical Trials Partnership (EDCTP) programme.
The EDCTP Association General Assembly officially approved Burundi’s membership on 24 September 2025, marking an important step in strengthening regional collaboration in global health research.
Burundi became the newest member country, bringing the total number of participating African countries to 31. By joining the Association, Burundi is now eligible for funding from the Global Health EDCTP3 programme and can contribute to the programme’s strategic direction.
Artemisinin resistance – A race against time
In May 2025, health officials from African countries where malaria is endemic and their international partners called for enhanced action to combat resistance to antimalarial drugs, a growing challenge that threatens to undermine hard-won progress in the fight against one of Africa’s deadliest diseases.
Held on the sidelines of the 78th World Health Assembly in Rwanda, this high-level gathering highlighted the urgent need for coordinated action to contain the spread of resistance to first-line antimalarial drugs.
‘Resistance to antimalarial drugs is a threat to all communities on this continent,’ said Dr Sabin Nsanzimana, Rwanda’s Minister of Health. “It requires a common response based on science, solidarity and speed. “
The side event brought together a powerful coalition of co-organisers, including Eritrea, Ethiopia, Namibia, South Sudan, Uganda, the United Republic of Tanzania and Zambia. Supporting partners included the World Health Organisation (WHO), Medicines for Malaria Venture (MMV), the RBM Partnership to End Malaria, and the Africa Centres for Disease Control and Prevention (Africa CDC). Combating resistance to antimalarial drugs is a key public health priority, particularly in the African region, which bears 95% of the global burden of malaria. According to the latest WHO World Malaria Report, four countries in East Africa – Eritrea, Rwanda, Uganda and the United Republic of Tanzania – have confirmed the presence of partial resistance to artemisinin, the main compound in the most effective treatments for P. falciparum malaria. Resistance is also suspected in other countries, including Ethiopia, Namibia, Sudan and Zambia.
Drug resistance is due to several factors, such as the use of substandard or counterfeit medicines and failure to complete treatment courses. Protecting the effectiveness of artemisinin-based antimalarial drugs is now a race against time. Given the heavy reliance on artemisinin-based combination therapies (ACTs) in Africa, a complete failure of treatment could have very serious consequences.









